Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

2nd Symposium Targeted Cancer Therapy

November 19 - 20, 2012, DKFZ Heidelberg, Communication Center


Breakthroughs in cancer research within the last decade have revolutionised our understanding of the molecular pathology of cancer. Nevertheless, the success of most of the currently available targeted cancer therapies is limited and the development of novel treatment options is slow. To accelerate the translation of research findings to novel therapeutics, the German Cancer Research Center (DKFZ) and Bayer HealthCare have joined forces and set up a strategic Alliance in 2008.

The Symposium is held within the framework of this partnership and is jointly organized by the DKFZ and Bayer HealthCare. It is the second of its kind and will bring together preclinical and clinical scientists to present their recent research findings relevant to the identification of novel targets or the development of novel therapeutic strategies.

The goal is to discuss established and emerging targeted cancer therapies. Scientific and clinical aspects will be reviewed in the context of oncogenomics, cancer stem cells, and immunotherapy. We cordially invite you to the stimulating environment and “scientific hot spot” of Heidelberg to discuss with us options to translate scientific ideas to novel treatment options.

Scientific Organizing Committee:
Philipp Beckhove, DKFZ. Volker Gekeler, BHC. Christof von Kalle, DKFZ, NCT. Bertolt Kreft, BHC. Peter Lichter, DKFZ. Dominik Mumberg, BHC. Andreas Trumpp, DKFZ. Otmar D. Wiestler, DKFZ. Karl Ziegelbauer, BHC.

to top
powered by webEdition CMS